PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2219 Views
-
Last post by NHE
-
- 0 Replies
- 1077 Views
-
Last post by NHE
-
- 0 Replies
- 11062 Views
-
Last post by NHE
-
- 0 Replies
- 2121 Views
-
Last post by Firidion
-
- 1 Replies
- 1365 Views
-
Last post by vesta
-
- 0 Replies
- 2109 Views
-
Last post by frodo
-
- 0 Replies
- 2027 Views
-
Last post by NHE
-
- 0 Replies
- 1531 Views
-
Last post by NHE
-
- 4 Replies
- 2545 Views
-
Last post by JohnC777